Literature DB >> 21449722

Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection.

Chris L Ayers1, Mihail Firan, Vinodh Pillai, William M Lee, Nitin J Karandikar.   

Abstract

Hepatitis C virus (HCV) has a propensity to establish chronic infection that is characterized by attenuated virus-specific T-cell responses. Mechanisms leading to T-cell attenuation are poorly understood and likely involve dysfunctional interactions between antigen-presenting cells (APC) and effector/regulatory T-cells. Reports on dendritic cells (DC) have described only minor dysfunction during HCV infection. However, there is a paucity of reports regarding B-cell function, despite clear associations with B-cell-related secondary sequelae. In this study we evaluated the state of B-cells during chronic HCV infection, and observed a diminished ability to respond to mitogenic stimuli, correlating with increased apoptosis. This was in contrast to their ex vivo phenotype, which indicated ongoing chronic activation in vivo. There was a high association of HCV-positive strand RNA with B-cells in a subset of HCV patients. Interestingly, ex-vivo-derived HCV RNA-positive B-cells induced significantly greater proliferation in allogeneic T-cells than in HCV-negative B-cells, correlating with an increased generation of CD4(+)CD25(+)FOXP3(+) regulatory T-cells (Tregs). In-vitro exposure of healthy peripheral blood mononuclear cells (PBMC) to HCV resulted in robust activation of resting B-cells. These HCV-exposed B-cells also showed an enhanced ability to generate Tregs. Our results provide strong evidence for a novel and paradoxical link between HCV-induced enhanced APC function and the generation of Tregs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21449722      PMCID: PMC3070003          DOI: 10.1089/vim.2010.0077

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  46 in total

1.  Analysis of a successful immune response against hepatitis C virus.

Authors:  S Cooper; A L Erickson; E J Adams; J Kansopon; A J Weiner; D Y Chien; M Houghton; P Parham; C M Walker
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

2.  Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: plasma HCV RNA analysis underestimates circulating virus load.

Authors:  W N Schmidt; P Wu; J Q Han; M J Perino; D R LaBrecque; J T Stapleton
Journal:  J Infect Dis       Date:  1997-07       Impact factor: 5.226

Review 3.  CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system.

Authors:  S Levy; S C Todd; H T Maecker
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

4.  Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.

Authors:  J T Gerlach; H M Diepolder; M C Jung; N H Gruener; W W Schraut; R Zachoval; R Hoffmann; C A Schirren; T Santantonio; G R Pape
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

5.  Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection.

Authors:  D K Wong; D D Dudley; N H Afdhal; J Dienstag; C M Rice; L Wang; M Houghton; B D Walker; M J Koziel
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

6.  Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection.

Authors:  Simon M Rushbrook; Scott M Ward; Esther Unitt; Sarah L Vowler; Michaela Lucas; Paul Klenerman; Graeme J M Alexander
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Triggering of target of an antiproliferative antibody-1 (TAPA-1/CD81) up-regulates the release of tumour necrosis factor-alpha by the EBV-B lymphoblastoid cell line JY.

Authors:  M Altomonte; R Montagner; C Pucillo; M Maio
Journal:  Scand J Immunol       Date:  1996-04       Impact factor: 3.487

8.  Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR.

Authors:  R E Lanford; C Sureau; J R Jacob; R White; T R Fuerst
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

9.  Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR.

Authors:  R E Lanford; D Chavez; F V Chisari; C Sureau
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles.

Authors:  S E Bassett; K M Brasky; R E Lanford
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

View more
  4 in total

1.  CD19+CD24hiCD38hi regulatory B cells: a potential immune predictive marker of severity and therapeutic responsiveness of hepatitis C.

Authors:  Qiannan Fang; Yanan Deng; Rongzhen Liang; Yongyu Mei; Zhaoxia Hu; Julie Wang; Jianbo Sun; Xiaohong Zhang; Joseph A Bellanti; Song Guo Zheng
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

2.  Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.

Authors:  Chris L Ayers; Jason P Mendoza; Sushmita Sinha; Khrishen Cunnusamy; Benjamin M Greenberg; Elliot M Frohman; Nitin J Karandikar
Journal:  Clin Immunol       Date:  2013-03-06       Impact factor: 3.969

3.  Effects of Friend Virus Infection and Regulatory T Cells on the Antigen Presentation Function of B Cells.

Authors:  Tyler C Moore; Ronald J Messer; Lorena M Gonzaga; Jennifer M Mather; Aaron B Carmody; Wibke Bayer; Elisabeth Littwitz-Salomon; Ulf Dittmer; Kim J Hasenkrug
Journal:  mBio       Date:  2019-01-22       Impact factor: 7.867

4.  Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+.

Authors:  Agnieszka Pawełczyk; Natalia Kubisa; Joanna Jabłońska; Iwona Bukowska-Ośko; Kamile Caraballo Cortes; Maria Fic; Tomasz Laskus; Marek Radkowski
Journal:  Virol J       Date:  2013-11-26       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.